These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 29512935

  • 1. Cytomegalovirus infections in lung and hematopoietic cell transplant recipients in the Organ Transplant Infection Prevention and Detection Study: A multi-year, multicenter prospective cohort study.
    Avery RK, Silveira FP, Benedict K, Cleveland AA, Kauffman CA, Schuster MG, Dubberke ER, Husain S, Paterson DL, Chiller T, Pappas P.
    Transpl Infect Dis; 2018 Jun; 20(3):e12877. PubMed ID: 29512935
    [Abstract] [Full Text] [Related]

  • 2. Paradoxical rising cytomegalovirus antigenemia during preemptive ganciclovir therapy in hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes.
    Park SY, Lee SO, Choi SH, Kim YS, Woo JH, Sung H, Kim MN, Kim DY, Lee JH, Lee JH, Lee KH, Kim SH.
    J Clin Microbiol; 2011 Dec; 49(12):4179-84. PubMed ID: 22031700
    [Abstract] [Full Text] [Related]

  • 3. Differences of cytomegalovirus diseases between kidney and hematopoietic stem cell transplant recipients during preemptive therapy.
    Kim T, Lee YM, Lee SO, Choi SH, Kim YS, Woo JH, Sung H, Jung JH, Shin S, Kim YH, Kang YA, Lee YS, Lee JH, Lee JH, Lee KH, Park SK, Han DJ, Kim SH.
    Korean J Intern Med; 2016 Sep; 31(5):961-70. PubMed ID: 27055664
    [Abstract] [Full Text] [Related]

  • 4. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
    Monforte V, Sintes H, López-Gallo C, Delgado M, Santos F, Zurbano F, Solé A, Gavaldá J, Borro JM, Redel-Montero J, Cifrian JM, Pastor A, Román A, Ussetti P.
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487
    [Abstract] [Full Text] [Related]

  • 5. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients.
    Tan SK, Waggoner JJ, Pinsky BA.
    J Clin Virol; 2015 Aug; 69():179-83. PubMed ID: 26209403
    [Abstract] [Full Text] [Related]

  • 6. Extending cytomegalovirus prophylaxis in high-risk (D+/R-) lung transplant recipients from 6 to 9 months reduces cytomegalovirus disease: A retrospective study.
    Herrera S, Khan B, Singer LG, Binnie M, Chaparro C, Chow CW, Martinu T, Tomlinson G, Keshavjee S, Husain S, Tikkanen JM.
    Transpl Infect Dis; 2020 Aug; 22(4):e13277. PubMed ID: 32170813
    [Abstract] [Full Text] [Related]

  • 7. Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients.
    Kim SJ, Huang YT, Foldi J, Lee YJ, Maloy M, Giralt SA, Jakubowski AA, Papanicolaou GA.
    Transpl Infect Dis; 2018 Jun; 20(3):e12881. PubMed ID: 29570237
    [Abstract] [Full Text] [Related]

  • 8. [Clinical study of low cytomegalovirus viral load thresholds for preemptive antiviral therapy in hematopoietic cell transplant recipients].
    Li L, Wang Y, Yan CH, Huang XJ.
    Zhonghua Nei Ke Za Zhi; 2018 Mar 01; 57(3):191-195. PubMed ID: 29518863
    [Abstract] [Full Text] [Related]

  • 9. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
    Mengelle C, Rostaing L, Weclawiak H, Rossignol C, Kamar N, Izopet J.
    J Med Virol; 2015 May 01; 87(5):836-44. PubMed ID: 25655981
    [Abstract] [Full Text] [Related]

  • 10. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW, Dubois D, Rothmeier C, Spiliopoulos A, Wunderli W, Nicod LP.
    Chest; 1999 Nov 01; 116(5):1265-72. PubMed ID: 10559085
    [Abstract] [Full Text] [Related]

  • 11. Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients.
    Jaamei N, Koutsokera A, Pasquier J, Mombelli M, Meylan P, Pascual M, Aubert JD, Manuel O.
    Transpl Infect Dis; 2018 Aug 01; 20(4):e12893. PubMed ID: 29603543
    [Abstract] [Full Text] [Related]

  • 12. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.
    Palmer SM, Limaye AP, Banks M, Gallup D, Chapman J, Lawrence EC, Dunitz J, Milstone A, Reynolds J, Yung GL, Chan KM, Aris R, Garrity E, Valentine V, McCall J, Chow SC, Davis RD, Avery R.
    Ann Intern Med; 2010 Jun 15; 152(12):761-9. PubMed ID: 20547904
    [Abstract] [Full Text] [Related]

  • 13. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
    Lin A, Maloy M, Su Y, Bhatt V, DeRespiris L, Griffin M, Lau C, Proli A, Barker J, Shaffer B, Giralt SA, Jakubowski AA, Papadopoulos EB, Papanicolaou GA, Seo SK, Perales MA.
    Transpl Infect Dis; 2019 Dec 15; 21(6):e13187. PubMed ID: 31585500
    [Abstract] [Full Text] [Related]

  • 14. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S, Katugaha SB, Cochrane A, Brown AW, Nathan SD, Shlobin OA, Ahmad K, Marinak L, Chun J, Fregoso M, Desai S, King C.
    Transpl Infect Dis; 2019 Dec 15; 21(6):e13166. PubMed ID: 31487755
    [Abstract] [Full Text] [Related]

  • 15. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
    Panagou E, Zakout G, Keshani J, Smith C, Irish D, Mackinnon S, Kottaridis P, Fielding A, Griffiths PD.
    Transpl Infect Dis; 2016 Jun 15; 18(3):405-14. PubMed ID: 27061703
    [Abstract] [Full Text] [Related]

  • 16. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients.
    Kruger RM, Paranjothi S, Storch GA, Lynch JP, Trulock EP.
    J Heart Lung Transplant; 2003 Jul 15; 22(7):754-63. PubMed ID: 12873543
    [Abstract] [Full Text] [Related]

  • 17. Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients.
    Wong DD, van Zuylen WJ, Craig ME, Rawlinson WD.
    Rev Med Virol; 2019 Mar 15; 29(2):e2023. PubMed ID: 30556615
    [Abstract] [Full Text] [Related]

  • 18. Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients.
    Fisher CE, Knudsen JL, Lease ED, Jerome KR, Rakita RM, Boeckh M, Limaye AP.
    Clin Infect Dis; 2017 Jul 01; 65(1):57-63. PubMed ID: 28369203
    [Abstract] [Full Text] [Related]

  • 19. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
    Nakamae H, Kirby KA, Sandmaier BM, Norasetthada L, Maloney DG, Maris MB, Davis C, Corey L, Storb R, Boeckh M.
    Biol Blood Marrow Transplant; 2009 Jun 01; 15(6):694-703. PubMed ID: 19450754
    [Abstract] [Full Text] [Related]

  • 20. Impact of donor and recipient cytomegalovirus serology on long-term survival of lung transplant recipients.
    Mabilangan C, Preiksaitis J, Cervera C, University of Alberta Cardiothoracic Transplant Group.
    Transpl Infect Dis; 2018 Oct 01; 20(5):e12964. PubMed ID: 29981174
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.